Covered recipient · General Payments record
JITEN VASANTLAL PATEL
Allopathic & Osteopathic Physicians Obstetrics & Gynecology Obstetrics
General Payments · PY2018–2024
$1,079.60
- Reported across 53 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $329.56 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Astellas Pharma US Inc | $76.67 | 3 |
| ABBVIE INC. | $40.80 | 2 |
| Organon LLC | $38.95 | 2 |
| MAYNE PHARMA COMMERCIAL LLC | $34.76 | 1 |
| Agile Therapeutics, Inc. | $26.94 | 2 |
| Smith & Nephew, Inc. | $23.30 | 1 |
| PFIZER INC. | $19.76 | 1 |
| Exeltis, USA Inc. | $18.85 | 1 |
| Gynesonics, Inc. | $18.16 | 1 |
| Currax Pharmaceuticals LLC | $15.89 | 1 |
| SHIELD THERAPEUTICS INC | $15.48 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $23.40 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105195124 | CMS |
| ABBVIE INC. | $17.40 | 02/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105195126 | CMS |
| Agile Therapeutics, Inc. | $13.16 | 01/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154845603 | CMS |
| Agile Therapeutics, Inc. | $13.78 | 06/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154842505 | CMS |
| Astellas Pharma US Inc | $23.88 | 02/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139285208 | CMS |
| Astellas Pharma US Inc | $23.98 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139335854 | CMS |
| Astellas Pharma US Inc | $28.81 | 10/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139415697 | CMS |
| Currax Pharmaceuticals LLC | $15.89 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089511806 | CMS |
| Exeltis, USA Inc. | $18.85 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150001546 | CMS |
| Gynesonics, Inc. | $18.16 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1128623431 | CMS |
| MAYNE PHARMA COMMERCIAL LLC | $34.76 | 11/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154694923 | CMS |
| Organon Llc | $23.37 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136194538 | CMS |
| Organon Llc | $15.58 | 04/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136313009 | CMS |
| PFIZER INC. | $19.76 | 02/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131032371 | CMS |
| SHIELD THERAPEUTICS INC | $15.48 | 06/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150134997 | CMS |
| Smith+Nephew, Inc. | $23.30 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1149609157 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.